Barry Patrick A 4
4 · Indivior Pharmaceuticals, Inc. · Filed Feb 12, 2026
Research Summary
AI-generated summary of this filing
Indivior (INDV) CCO Barry Patrick Receives RSU Award
What Happened
Barry Patrick, Chief Commercial Officer of Indivior Pharmaceuticals (INDV), received a grant of 31,380 restricted stock units (RSUs) on February 10, 2026. The filing shows an acquisition price of $0, consistent with an equity award rather than an open-market purchase. The RSUs represent a contingent right to receive one share per RSU subject to vesting.
Key Details
- Transaction date: 2026-02-10 (reported on Form 4 filed 2026-02-12).
- Transaction type/code: Award/Grant (A). Price reported: $0.
- Shares granted: 31,380 RSUs.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- Footnote: Each RSU vests in three equal annual installments beginning Feb 10, 2027, subject to continued service. (Footnote F1)
- Filing timeliness: Report appears timely (filed two days after the grant).
- Remarks: Exhibit 24 Power of Attorney included with the filing.
Context
RSU grants are compensation awards that vest over time and do not represent an immediate cash purchase or sale. Because these RSUs vest in installments, the shares will only be delivered if Mr. Patrick remains employed through each vesting date. This type of award is commonly used to align executive incentives with long-term shareholder value.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-10+31,380→ 31,380 total
Footnotes (1)
- [F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.